

Inetetamab

Cat. No.:	HY-P99969
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities ^{[1][2]} .	
IC₅₀ & Target	HER2	
In Vivo	Inetetamab (20 mg/kg, i.p.) shows antitumor effects in the JIMT-1 xenograft mouse model ^[2] .	
	Inetetamab (20 mg/kg, i.p.) together with Pyrotinib or Cyclophosphamide also has distinct antitumor effects in JIMT-1 and NCI-N87 xenograft mouse model ^[2] .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	JIMT-1 xenograft mouse model ^[2]
	Dosage:	20 mg/kg, or together with Pyrotinib (20 mg/kg, p.o.) or Cyclophosphamide (10 mg/kg, p.o.)
Administration:	i.p, twice a week	
Result:	Inhibited tumor growth with a tumor growth inhibition (TGI) rate of approximately 40%, and induces a stronger synergistic antitumor effect with Pyrotinib or Cyclophosphamide.	

REFERENCES

[1]. Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. *Journal of Clinical Oncology*. 2022. 40 (16), e13030-e13030.

[2]. Deng L, et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. *Open Life Sci*. 2023 Jan 10;18(1):20220535.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA